| Role |
Name |
Disclosure |
Details |
| Author | Mark Jeffrey Noble, MD, Consulting Staff, Urologic Institute, Cleveland Clinic Foundation | Nothing to disclose | Details | | Coauthor | Milton Lakin, MD, Head, Section of Medical Urology, Urological Institute, Cleveland Clinic | Nothing to disclose | Details | | Medical Editor | Leonard Gabriel Gomella, MD, FACS, The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Thomas Jefferson University | GSK Astra Zeneca | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | CME Editor | J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center | Terumo Corporation Omeros Corporation | Details | | Chief Editor | Stephen W Leslie, MD, FACS, Founder and Medical Director of the Lorain Kidney Stone Research Center, Clinical Assistant Professor, Department of Urology, Medical College of Ohio | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Mark Jeffrey Noble, Author |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Milton Lakin, Coauthor |
The contributor discloses no conflict of interest. |
|